FdaApplication
BLA 125787
Identifiers
- fda_app_no: BLA125787
Properties
| Property | Value |
|---|---|
| applicant_name | Vertex Pharmaceuticals Inc |
| application_type | BLA |
| approval_date | 2023-12-08 |
Revenue by product
CASGEVY
| Period | Revenue |
|---|---|
| Q2 2026 | $76.4M |
| Q1 2026 | $42.9M |
| Q4 2025 | $54.3M |
| Q3 2025 | $16.9M |
| Q2 2025 | $30.4M |
| Q1 2025 | $28.4M |
| Q4 2024 | $8.0M |
| Q3 2024 | $2.0M |
| Q2 2024 | $0.0M |
| Q1 2024 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CASGEVY | — | 4-13 10^6 CELL/ML | Suspension |
1 product